A Novel Method for Determination of Thromboembolic Stroke Origin
- Conditions
- Thromboembolic Stroke
- Interventions
- Drug: NaF PET-CT
- Registration Number
- NCT06961604
- Lead Sponsor
- Atlantic Health System
- Brief Summary
Rupture of vulnerable carotid, vertebral, and intracranial arterial plaques results in thromboembolic stroke. Identification of these culprit lesions is an important component of post-stroke care. This study seeks to test the feasibility of NaF PET-CT to detect these plaques and alter patient care. Prior studies have shown a high degree of correlation between NaF PET+ lesions and high-risk plaque features on high resolution MRI, including mirocalcification, necrosis, and ulceration.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 20
18 years of age or older with a non-cardiogenic thromboembolic stroke in the past 14 days.
Less than 18 years of age, any other kind of stroke, not clinically stable to undergo PET-CT
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Intervention - NaF PET NaF PET-CT Intervention/Experimental Arm - non-cardiogenic thromboembolic stroke patients to undergo NaF PET-CT
- Primary Outcome Measures
Name Time Method Culprit lesion Within 14 days of the stroke Can NaF PET-CT within 14 days of a non-cardiogenic thromboembolic stroke identify the likely culprit plaque as a source of the stroke
- Secondary Outcome Measures
Name Time Method Recurrent stroke Within 1 year of imaging Can NaF PET-CT within 14 days of a non-cardiogenic thromboembolic stroke predict the location of a future non-cardiogenic thromboembolic stroke
Management change Within 1 year of imaging Can NaF PET-CT within 14 days of a non-cardiogenic thromboembolic stroke alter patient management
Trial Locations
- Locations (1)
Overlook Medical Center
🇺🇸Summit, New Jersey, United States